Registration for interest in the Sinopharm vaccine is now available. Register your interest.
What you need to know about Janssen vaccine
Developed by Janssen (Johnson & Johnson), the COVID-19 vaccine Ad26.COV2.S (Janssen) vaccine is the first single dose COVID-19 vaccine to be approved by the World Health Organisation for emergency listing.
What’s different about the Janssen vaccine?
Only single-dose COVID-19 vaccine available
Currently the Janssen vaccine is the only single-dose COVID-19 vaccine approved by the WHO for emergency use.
Has a long shelf life of two years
While the vaccine must be stored in -20 degrees Celcius, it has a shelf life of two years.
Developed by Johnson & Johnson
This single-dose COVID-19 vaccine was developed by Janssen Pharmaceuticals, a pharmaceutical arm of Johnson & Johnson
Who is eligible for taking Janssen?
 |
Individuals aged 18 years and older, with no history of anaphylaxis. |
What is the recommended dosage for administration?
|
Single-dose administration of the Janssen vaccine with a minimal of 14 days interval for any other vaccines for health conditions. |
How safe is Janssen?
Based on existing studies, 28 days after inoculation, Janssen vaccine has an efficacy of 85.4% against severe disease and hospitalisation as well as an efficacy of 66.9% against symptomatic moderate and severe COVID-19 infection
